{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:50:50Z","timestamp":1740178250753,"version":"3.37.3"},"reference-count":5,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.1182\/bloodadvances.2024014102","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T20:59:25Z","timestamp":1723064365000},"page":"5927-5928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Improving reporting of infection events in clinical trials"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"1Wilhelminen Cancer Research Institute, Department of Medicine I, Clinic Ottakring, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute and Boston VA Healthcare System, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"3Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"4Department of Hematology\/Oncology, Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"5Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2024112616203548300_bib1","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013859","article-title":"Improving infection reporting in hematology treatment trials","author":"Teh","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2024112616203548300_bib2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen\u00a0(BCMA) in multiple myeloma: rationale for targeting and current\u00a0therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"2024112616203548300_bib3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 3","key":"2024112616203548300_bib4","doi-asserted-by":"crossref","first-page":"e15362d7","DOI":"10.1097\/01.HS9.0000967672.15362.d7","article-title":"First results from the REDIRECTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Mateos","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024112616203548300_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5927\/2316138\/blooda_adv-2024-014102-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5927\/2316138\/blooda_adv-2024-014102-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:20:55Z","timestamp":1732638055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5927\/517298\/Improving-reporting-of-infection-events-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":5,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014102","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}